The HIV Diagnostics Market is a core segment of the global infectious disease diagnostics industry, focused on the detection, confirmation, and monitoring of HIV infection across screening, diagnosis, treatment initiation, early infant diagnosis, and long-term care pathways. The market serves hospitals, central laboratories, blood banks, public health testing programs, antenatal clinics, community testing networks, pharmacies, and increasingly home-based consumer channels. Key applications include routine screening, diagnosis of acute infection, confirmatory testing after an initial reactive result, testing to support prevention services, infant testing in exposed newborns, and viral load monitoring in treated patients. Recent trends show a clear shift from antibody-only approaches toward a broader mix of lab-based antigen/antibody assays, rapid point-of-care formats, nucleic acid testing for earlier detection, and self-testing models that improve convenience and reach. The category is also moving toward more differentiated service delivery, with stronger integration of facility-based, community-based, and self-directed testing pathways.